How Much Medivation Can Really Fetch in a Buyout
Medivation has been among the top future biotech mergers for quite some time. The problem is that we still have no idea which company will buy Medivation, nor do we know what price.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 200
Thursday’s Top Health Care Stocks Punishing Investors
On Thursday, a few companies in the biotech and pharmaceutical industries made substantial runs. In this case it was all downward.
Why Valeant Got Its First Big Analyst Upgrade of 2016
Although some analysts have become less negative and upgraded to a more neutral view on Valeant Pharmaceuticals, Morgan Stanley's is a true call to buy the stock.
Tuesday’s Top Health Care Movers
On Tuesday, a few biotech companies made substantial runs, either up and down, due to the results of FDA approvals, failed or passed trials and even earnings results.
Why Every Analyst in the World Loves Patheon Even After a Strong IPO
Patheon saw its quiet period come to an end on Monday, and the analyst floodgates opened wide. What stood out so much here was that the analyst ratings seem universally positive.
Can Eleven Biotherapeutics Keep Climbing With This Roche Deal?
Eleven Biotherapeutics is continuing to rise this week after the company announced the effectiveness of the exclusive licensing deal with Roche.
Credit Suisse Issues Top Pharma Picks in Bull/Bear Upside Analysis
Credit Suisse has run bullish and bearish scenarios for what the firm feels is a reasonable upside and downside for each of its large cap pharmaceutical stocks.
Why Aurinia Pharma Is Getting Slaughtered
Shares of Aurinia Pharmaceuticals were halved early in Monday’s session following a mid-stage trial hiccup.
3 Top Health Care REITs Are Still Paying Outstanding Dividends
One sector that continues to grow is health care, and the health care real estate investment trusts that have traded higher still offer outstanding distributions.
Why This Analyst Sees Huge Upside for Valeant and 2 More Specialty Pharmas
All three of these specialty pharmaceutical stocks come with a fair share of risk but provide big upside potential as well.
5 Biohealth Stocks Rising 10% or More on News
A few biohealth companies made absolutely massive runs in Thursday’s session. The companies 24/7 Wall St. has picked stood out from the rest with big moves, all at least up 10%.
Why Jefferies Sees 3 Big Biotechs Having Key Upside Catalysts Coming
Investors are now focusing on fundamentals and near-term catalysts that could provide a tailwind for some of the biotech leaders.
Two Polar Opposite Views on GW Cannabinoid Drug Upside
GW Pharmaceuticals PLC (NASDAQ: GWPH) was seeing some selling pressure after the company reported earnings. Its third quarter loss was actually better than expected, but revenues of $3.1 million were softer than expected. What most…
Why Analysts Are Abandoning Myriad Genetics Upside Hopes
24/7 Wall St. could not help but notice how many analysts on Wall Street have simply abandoned their old upside hopes for Myriad Genetics.
Major Pharma Short Interest Slides
The July 29 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest was lower.